Adjunctive molecular hydrogen therapy for refractory malar rash in systemic lupus erythematosus: A case report with immunological insights.
Nai-Sung Hsu, Jeng-Wei Lu, Hsiao-Chen Liu, Yi-Jung Ho, Kuang-Yih Wang, Feng-Cheng Liu · SAGE open medical case reports · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In While hydroxychloroquine is standard therapy, some cases remain treatment-resistant, after initiating oral molecular hydrogen therapy, the patient showed sustained clinical improvement, including reduced malar rash, decreased fatigue, and enhanced well-being over several months. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in While hydroxychloroquine is standard therapy, some cases remain treatment-resistant. After initiating oral molecular hydrogen therapy, the patient showed sustained clinical improvement, including reduced malar rash, decreased fatigue, and enhanced well-being over several months.
What the Researchers Studied
The researchers studied While hydroxychloroquine is standard therapy, some cases remain treatment-resistant.
What Effects Did Molecular Hydrogen Have?
This case report examines the use of molecular hydrogen as adjunctive therapy in a 27-year-old woman with systemic lupus erythematosus and refractory malar rash. After initiating oral molecular hydrogen therapy, the patient showed sustained clinical improvement, including reduced malar rash, decreased fatigue, and enhanced well-being over several months. The authors concluded that this case suggests that molecular hydrogen may be a safe and promising adjunctive treatment for cutaneous manifestations and systemic immune modulation in systemic lupus erythematosus. Molecular hydrogen possesses anti-inflammatory and immunomodulatory effects in autoimmune disorders. sj-pdf-1-sco-10.1177_2050313X251372755 – Supplemental material for Adjunctive molecular hydrogen therapy for refractory malar rash in systemic lupus erythematosus: A case report with immunological insights Supplemental material, sj-pdf-1-sco-10.1177_2050313X251372755 for Adjunctive molecular hydrogen therapy for refractory malar rash in systemic lupus erythematosus: A case report with immunological insights by Nai-Sung Hsu, Jeng-Wei Lu, Hsiao-Chen Liu, Yi-Jung Ho, Kuang-Yih Wang and Feng-Cheng Liu in SAGE Open Medical Case Reports.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was While hydroxychloroquine is standard therapy, some cases remain treatment-resistant.
Limitations and Safety
Reported limitations: However, a key limitation of this report is the concurrent use of hydroxychloroquine alongside H₂ therapy, which complicates the attribution of clinical improvement solely to hydrogen treatment.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.